Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.43 |
| ▸ | CFD | P00746 | 13/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3626923 | 0.92 | TSHR (0.40) | METTL3CFDKLKB1TSHRP2RX7 | |
| SCHEMBL3620073 | 0.91 | METTL3 (0.38) | METTL3CFDKLKB1P2RX7 | |
| SCHEMBL3627435 | 0.91 | CFD (0.42) | METTL3CFDP2RX7 | |
| SCHEMBL3623481 | 0.91 | METTL3 (0.41) | METTL3CFDKLKB1P2RX7 | |
| SCHEMBL3627371 | 0.91 | CFD (0.41) | METTL3CFDKLKB1P2RX7 | |
| SCHEMBL3624957 | 0.90 | CFD (0.39) | METTL3CFDKLKB1P2RX7 | |
| SCHEMBL3625163 | 0.89 | CFD (0.44) | METTL3CFDP2RX7 | |
| SCHEMBL3628891 | 0.89 | CFD (0.42) | METTL3CFDKLKB1P2RX7 | |
| SCHEMBL3626500 | 0.89 | METTL3 (0.42) | METTL3CFDKLKB1 | |
| SCHEMBL3625726 | 0.89 | METTL3 (0.42) | METTL3CFDKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745459-B2 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-06-29 | — | — | US | claimed |
| US-20060084665-A1 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-04-20 | — | — | US | claimed |
| US-7745459-B2 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-7745459-B2 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-7745459-B2 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20060084665-A1 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084665-A1 | Quinolizinone compound and use thereof as HIV integrase inhibitor | NQO2, ACE, CDK20 | METTL3 3971/4885CFD 4484/4885KLKB1 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.